检索结果 - Takayo Inoue

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer

    Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer 由 Cheryl A. London, Misty D. Bear, Jennifer McCleese, Kevin P. Foley, Reji Paalangara, Takayo Inoue, Weiwen Ying, James Barsoum

    出版 2011
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors

    A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors 由 Dan Zhou, Yuan Liu, Josephine Ye, Weiwen Ying, Luisa Shin Ogawa, Takayo Inoue, Noriaki Tatsuta, Yumiko Wada, Keizo Koya, Qin Huang, Richard C. Bates, Andrew J. Sonderfan

    出版 2013
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

    A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid ma... 由 Jonathan W. Goldman, Robert N. Raju, Gregory Gordon, Iman El‐Hariry, Florentina Teofilivici, Vojo Vukovic, Robert Bradley, Michael D. Karol, Yu Chen, Wei Guo, Takayo Inoue, Lee S. Rosen

    出版 2013
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism

    FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism 由 Jaime Acquaviva, Suqin He, Chaohua Zhang, John-Paul Jimenez, Masazumi Nagai, Jim Sang, Manuel Sequeira, Donald L. Smith, Luisa Shin Ogawa, Takayo Inoue, Noriaki Tatsuta, Margaret A. Knowles, Richard C. Bates, David A. Proia

    出版 2014
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

    Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy 由 Weiwen Ying, Zhenjian Du, Lijun Sun, Kevin P. Foley, David A. Proia, Ronald K. Blackman, Dan Zhou, Takayo Inoue, Noriaki Tatsuta, Jim Sang, Shuxia Ye, Jamie Acquaviva, Luisa Shin Ogawa, Yumiko Wada, James Barsoum, Keizo Koya

    出版 2011
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer

    Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer 由 Takeshi Shimamura, Samanthi A. Perera, Kevin P. Foley, Jim Sang, Scott J. Rodig, Takayo Inoue, Liang Chen, Danan Li, Julián Carretero, Yuchen Li, Papiya Sinha, Christopher D. Carey, Christa L. Borgman, John-Paul Jimenez, Matthew Meyerson, Weiwen Ying, James Barsoum, Kwok‐Kin Wong, Geoffrey I. Shapiro

    出版 2012
    获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: